BioWorld’s suite of news services delivers actionable intelligence on the most innovative therapeutics and medical technologies in development. With writers and editors stationed around the globe, BioWorld reports the breaking news – and provides key perspective on hundreds of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes.
BioWorld has a long tradition of excellence in journalism. Collectively, the news services have been honored with 77 awards from the Specialized Information Publishing Association and Apex dating back to 1998.
BioWorld remains committed to the core principles of ethical journalism, producing fact-based news and analysis via direct interviews with sources and intensive background research bolstered with invaluable data from BioWorld’s vast archives and other trusted data sources. We are constantly working to enhance our news products. Read about BioWorld’s latest efforts, such as special reports, awards and recognition:
BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards
BioWorld by Clarivate Recognized for Excellence in Publishing
Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report
BioWorld by Clarivate Explores the Concept of Extending Human Lifespan in New Report
Clarivate Deals Report Highlights Emerging Trends in Biopharma Deal-Making
BioWorld by Clarivate Identifies the Top Six Global Biopharmaceutical Stories and Trends of 2021
BioWorld Recognized for Excellence of Information & Intelligence to Biopharmaceutical Industry
BioWorld
BioWorld was launched as a magazine in 1990 by David Bunnell and Cynthia Robbins-Roth (a former scientist from Genentech). Bunnell was a pioneer of the personal computing industry who founded some of the most successful computer magazines, including PC Magazine, PC World and Macworld. He had the idea that biotechnology would become a big thing, and he was right! Early on, BioWorld was converted to a faxed publication, called BioWorld Today. Shortly after, BioWorld Financial Watch (a weekly look at financial trends) was launched along with a nascent data service that tracked the biopharmaceutical industry. BioWorld’s former owner, Thompson Media Group, acquired BioWorld in 1994. BioWorld dropped the faxed version and converted to digital delivery. BioWorld was acquired by Thomson Reuters in 2013. In 2016 Thomson Reuters spun off the Intellectual Property and Science division, which emerged as an independent company now known as Clarivate.
BioWorld MedTech
The assets of Biomedical Business International were acquired in 1994. The flagship publication, The BBI Newsletter, was converted to a weekly for the med-tech industry in 1997. In 2001, it became Medical Device Daily. In 2017, the news service was rebranded as BioWorld MedTech.
BioWorld Science
Originally called Prous Science Daily Essentials, this news service was renamed several times since it was launched in 1996. BioWorld Science joined the group in 2018 with a focus on discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages every business day. Readers who need more technical details will find that BioWorld Science delivers competitive scientific intelligence about novel compounds and those in development across all therapy areas drawn from multiple information sources.
BioWorld Asia
In response to a rapidly increasing demand for more news from this region, BioWorld Asia was launched in 2013 to provide biopharmaceutical executives with a trusted, steady stream of intelligence from this critical part of the world.
BioWorld publishes every business day with the following exceptions:
2025-26 nonpublishing days*
| BioWorld and BioWorld MedTech | BioWorld Science | BioWorld Asia |
|
Nov. 27 and 28, Thanksgiving
|
Dec. 25 and 26, Christmas
|
Dec. 25 and 26, Christmas
|
| *Dates are subject to change | ||